(Reuters) Pfizer Inc. announced on Wednesday that booster doses of its COVID-19 vaccine can be administered alongside its pneumonia vaccine. The vaccine has shown high safety responses in patients aged 65 and over in a study of late-stage.
The study, initiated in May, tested the company’s next-generation pneumococcal vaccine PREVNAR 20, with the third dose of the Pfizer-BioNTech COVID-19 shot in 570 participants.
The goal of the study was to determine the safety of the combination and the immune response following the addition of the pneumonia vaccine to the COVID-19 vaccine.
According to the company, the responses to PREVNAR 20 or the booster dose of COVID-19 vaccine were comparable when administered in combination with placebo.
Pfizer has stated in a press release that the research suggests that it is possible to administer PREVNAR 20 as well as COVID-19 at the same time which would reduce the number of visits people make to their doctor or pharmacy for recommended vaccinations.
The U.S. Food and Drug Administration approved PREVNAR 20 in June 2013 to safeguard adults from the most serious and invasive pneumococcal diseases and pneumonia.
Participants in the study were selected from COVID-19 late-stage vaccine studies of the companies. They also included those who had received the second dose at least six months prior to joining the study.
Content Source: https://www.medscape.com/viewarticle/966453?src=rss